Atlas Trials

Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM

Clinical trial NCT05285046 · UNKNOWN

Trial details

NCT number
NCT05285046
Sponsor
D'Or Institute for Research and Education
Status
UNKNOWN
Study type
OBSERVATIONAL
Bacterial InfectionsAntibiotic Resistant Infection
Start date
2022-04-01
Primary completion
2022-10-30
Enrollment
250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.